Radiology CME

Credits: 1.50 CME
Penn State College of Medicine
Contemporary Management Strategies in STS: Targeted and Cytotoxic Treatment Options to Optimize Patient Outcomes
1 December, 2017
Credits: 1.50 CME / CE / CPE
Medical Learning Institute, Inc.
Understanding the Impact of Immunotherapy on Head and Neck Cancer: A Look at the Science, Practice, and Future of Multimodal Treatment

Understanding the Impact of Immunotherapy on Head and Neck Cancer: A Look at the Science, Practice, and Future of Multimodal Treatment

Start

Activity Description and Educational Objectives

Treatment options for patients with squamous cell cancer of the head and neck (SCCHN), including recurrent/metastatic SCCHN, have expanded with the rapid integration of immunotherapy into modern oncology. In particular, checkpoint blockade has become an important component of multimodal head and neck cancer (HNC) care. Currently, researchers are attempting to answer the question of how exactly immune checkpoint blockade will pair with existing treatment modalities, such as radiotherapy, in the HNC setting; and what this further integration of immune therapy will mean for patients with recurrent/metastatic or locally advanced HNC. This activity features insight from expert clinicians as they attempt to answer these issues in HNC while offering thoughts on a patient’s experience of several modes of therapy, including radiation and immune treatment; based on a recent live symposium held at the 2017 American Society of Radiation Oncology (ASTRO) Annual Meeting.

Upon completion of this activity, participants will be able to:
  • Describe updated efficacy and safety evidence on the use of immunotherapy in a range of SCCHN treatment settings, including recurrent/metastatic or locally advanced disease, among others
  • Summarize evidence on novel combination options for SCCHN, including immune combinations, immunotherapy radiotherapy, and other multimodal approaches
  • Recommend treatment with immunotherapy for eligible patients with SCCHN, including individuals eligible for clinical trial–based treatment
  • Recognize and manage unique response dynamics or adverse events in patients with SCCHN receiving immunotherapy, radiotherapy-immunotherapy, or other multimodal combinations

Target Audience

This activity has been designed to meet the educational needs of radiation, medical and surgical oncologists, advanced practice nurses, pharmacists, and other clinicians involved in the management of patients with squamous cell cancer of the head and neck.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of squamous cell cancer of the head and neck.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 02, 2017 - November 01, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE/CPE activity during the past 12 months.

Course Director and Moderator

Robert L. Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
Pittsburgh, Pennsylvania

Robert L. Ferris, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck & Co., Inc.; and VentiRx Pharmaceuticals.
Advisory Board for Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and PPD (Benitec Biopharma).
Robert L. Ferris, MD, PhD, does intend to discuss either non-FDA approved or investigational use for the following products/devices: several immune therapies currently in testing for various SCHNN populations, including durvalumab, nivolumab, pembrolizumab, lirilumab, epacadostat, and other immune-stimulating therapies.

Faculty

Ezra Cohen, MD, FRCPC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
UC San Diego
Co-director, San Diego Center for Precision Immunotherapy
Associate Director for Translational Science
UC San Diego Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
Co-director, Head and Neck Cancer Center of Excellence
La Jolla, California

Ezra Cohen, MD, FRCPC, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bristol-Myers Squibb; Eisai Inc.; Human Longevity, Inc.; Merck & Co., Inc.; and Pfizer.
Ezra Cohen, MD, FRCPC, FASCO, does intend to discuss either non-FDA approved or investigational use for the following products/devices: several immune therapies currently in testing for various SCHNN populations, including durvalumab, nivolumab, pembrolizumab, lirilumab, epacadostat, and other immune-stimulating therapies.

Quynh-Thu Le, MD, FACR, FASTRO
Katharine Dexter McCormick & Stanley McCormick Memorial Professor
Professor and Chair
Department of Radiation Oncology
Stanford University
Stanford, California

Quynh-Thu Le, MD, FACR, FASTRO, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb.
Grant/Research Support from Amgen Inc.; RedHill; and Varian Medical Systems, Inc.
Quynh-Thu Le, MD, FACR, FASTRO, does intend to discuss either non-FDA approved or investigational use for the following products/devices: several immune therapies currently in testing for various SCHNN populations, including durvalumab, nivolumab, pembrolizumab, lirilumab, epacadostat, and other immune-stimulating therapies.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Bobbie Perrin, RN, OCN
Harrington Cancer Center
Amarillo, Texas

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

CPE Reviewer

Nancy Nesser, JD, PharmD
Oklahoma Health Care Authority
Oklahoma City, OK

Nancy Nesser, JD, PharmD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.

Pharmacists

ACPE The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-17-014-H01-P.

Providership

This CME/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Collaboration Statement

This activity was developed in collaboration with the Head and Neck Cancer Alliance (HNCA).

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView
2 November, 2017
Credits: 1.50 CME / CE
Medical Learning Institute, Inc.
New Options and Evolving Strategies for Hitting the Target in EGFR-Mutant Non–Small-Cell Lung Cancer: Navigating the Transitions in the EGFR TKI Treatment Landscape in the Era of Precision Oncology

New Options and Evolving Strategies for Hitting the Target in EGFR-Mutant Non–Small-Cell Lung Cancer: Navigating the Transitions in the EGFR TKI Treatment Landscape in the Era of Precision Oncology

Start

Activity Description and Educational Objectives

The management of advanced/metastatic EGFR-positive NSCLC is in a state of flux, and the treatment landscape is being shaken up by new, exciting research and clinical trial findings. In this educational activity, which is based on a Live Master Class and Practicum, experts in lung cancer explore the latest evidence and provide guidance for how to effectively navigate the molecular testing options throughout the continuum of the disease, as well as the complex clinical decisions regarding choice of EGFR TKI therapy in the first-line setting and beyond.

Upon completion of this activity, participants will be able to:

  • Discuss the role and optimal use of tissue- and blood-based biomarker testing methodologies for detection of EGFR mutations in different settings throughout the disease course
  • Analyze the efficacy/safety and clinical roles of standard and novel EGFR TKIs and combination strategies in the first-line treatment of advanced EGFR mutation-positive NSCLC
  • Assess the efficacy/safety and clinical roles of approved and investigational therapies and combinations for management of NSCLC with acquired resistance to initial EGFR TKIs
  • Implement best practices for individualized, genotype-directed, evidence-based management of patients with NSCLC exhibiting EGFR mutations throughout the continuum of advanced disease

Target Audience

This activity has been designed to meet the educational needs of thoracic oncology specialists and other healthcare professionals involved in the management of patients with lung cancer.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of advanced EGFR mutation-positive NSCLC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 27, 2017 - October 26, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity during the past 12 months.

Course Director and Moderator

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Lecia V. Sequist, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Genentech, Inc.; Merrimack Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Lecia V. Sequist, MD, MPH, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Targeted therapies and/or combination for EGFR-positive lung cancer and platforms for detecting EGFR mutations.

Faculty

Mary Jo Fidler, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Cell Therapy
Rush University Medical Center
Chicago, Illinois

Mary Jo Fidler, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Celgene Corporation; Genentech, Inc.; and Merck & Co., Inc.
Advisory Board for AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; and Takeda Pharmaceuticals U.S.A., Inc.
Other Financial or Material Support from Spouse who is also a consultant for Genentech, Inc.
Mary Jo Fidler, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Targeted therapies and/or combination for EGFR-positive lung cancer and platforms for detecting EGFR mutations.

Jyoti D. Patel, MD
Professor of Medicine
Section of Hematology\Oncology
The University of Chicago
Chicago, Illinois

Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc. and ARIAD Pharmaceuticals, Inc.
Jyoti D. Patel, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Targeted therapies and/or combination for EGFR-positive lung cancer and platforms for detecting EGFR mutations.

CME Reviewer

Amer Assal, MD
Columbia University Medical Center
Blood and Marrow Transplantation Program
New York, New York

Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Pamela Ash, RN, MSN, CBCN
Supportive Care Nurse Clinician
Mary Babb Randolph Cancer Center Clinic
West Virginia University
Morgantown, West Virginia

Pamela Ash, RN, MSN, CBCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.

Providership

This CME/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView

27 October, 2017

Pages